Advertisement

Obesity, Inflammation, Nonalcoholic Fatty Liver Disease, and Hepatocellular Carcinoma

  • Naim Alkhouri
  • Arthur McCullough
Chapter
Part of the Energy Balance and Cancer book series (EBAC, volume 7)

Abstract

  • Hepatocellular carcinoma (HCC) is a common malignancy worldwide that is increasing in incidence in the United States.

  • Viral and alcohol-related liver diseases account for most cases; however, a significant number of patients with HCC do not have a known underlying chronic liver disease.

  • New evidence suggests that obesity and type 2 diabetes may play a significant role in the development of HCC.

  • Nonalcoholic fatty liver disease (NAFLD) is very common in patients with obesity and diabetes and may progress to cirrhosis and HCC.

  • Insulin resistance, adipose tissue inflammation, adipokines, and inflammatory cytokines comprise mechanistic pathways that link obesity with NAFLD and HCC.

Keywords

Alcoholic Liver Disease Nonalcoholic Fatty Liver Disease Primary Liver Cancer NAFLD Patient NASH Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedCrossRefGoogle Scholar
  2. 2.
    Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42(suppl 3):S206–S214PubMedCrossRefGoogle Scholar
  3. 3.
    El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118–1127PubMedCrossRefGoogle Scholar
  4. 4.
    McGlynn KA, London WT (2011) The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 15:223–243, vii–xGoogle Scholar
  5. 5.
    Page JM, Harrison SA (2009) NASH and HCC. Clin Liver Dis 13:631–647PubMedCrossRefGoogle Scholar
  6. 6.
    Calle EE, Rodriguez C, Walker-Thurmond K et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRefGoogle Scholar
  7. 7.
    Moller H, Mellemgaard A, Lindvig K et al (1994) Obesity and cancer risk: a Danish record-­linkage study. Eur J Cancer 30A:344–350PubMedCrossRefGoogle Scholar
  8. 8.
    Wolk A, Gridley G, Svensson M et al (2001) A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12:13–21PubMedCrossRefGoogle Scholar
  9. 9.
    El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380PubMedCrossRefGoogle Scholar
  10. 10.
    El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460–468PubMedCrossRefGoogle Scholar
  11. 11.
    Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:1820–1832PubMedCrossRefGoogle Scholar
  12. 12.
    Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115:1111–1119PubMedGoogle Scholar
  13. 13.
    Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860–867PubMedCrossRefGoogle Scholar
  14. 14.
    Weisberg SP, McCann D, Desai M et al (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808PubMedGoogle Scholar
  15. 15.
    Jou J, Choi SS, Diehl AM (2008) Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28:370–379PubMedCrossRefGoogle Scholar
  16. 16.
    Wree A, Kahraman A, Gerken G et al (2010) Obesity affects the liver—the link between adipocytes and hepatocytes. Digestion 83:124–133PubMedCrossRefGoogle Scholar
  17. 17.
    Alkhouri N, Dixon LJ, Feldstein AE (2009) Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 3:445–451PubMedCrossRefGoogle Scholar
  18. 18.
    Listenberger LL, Han X, Lewis SE et al (2003) Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 100:3077–3082PubMedCrossRefGoogle Scholar
  19. 19.
    Unger RH (2002) Lipotoxic diseases. Annu Rev Med 53:319–336PubMedCrossRefGoogle Scholar
  20. 20.
    Guicciardi ME, Gores GJ (2005) Apoptosis: a mechanism of acute and chronic liver injury. Gut 54:1024–1033PubMedCrossRefGoogle Scholar
  21. 21.
    Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218PubMedGoogle Scholar
  22. 22.
    Friedman SL (2003) Liver fibrosis—from bench to bedside. J Hepatol 38(suppl 1):S38–S53PubMedCrossRefGoogle Scholar
  23. 23.
    Seitz HK, Stickel F (2006) Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 387:349–360PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang DY, Friedman SL (2012) Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 56:769–775PubMedCrossRefGoogle Scholar
  25. 25.
    Tanaka S, Mohr L, Schmidt EV et al (1997) Biological effects of human insulin receptor substrate-­1 overexpression in hepatocytes. Hepatology 26:598–604PubMedCrossRefGoogle Scholar
  26. 26.
    Hirosumi J, Tuncman G, Chang L et al (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333–336PubMedCrossRefGoogle Scholar
  27. 27.
    Puri P, Mirshahi F, Cheung O et al (2008) Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 134:568–576PubMedCrossRefGoogle Scholar
  28. 28.
    Chang Q, Zhang Y, Beezhold KJ et al (2009) Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol 50:323–333PubMedCrossRefGoogle Scholar
  29. 29.
    Hui L, Zatloukal K, Scheuch H et al (2008) Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 118:3943–3953PubMedCrossRefGoogle Scholar
  30. 30.
    Shen C, Zhao CY, Zhang R et al (2012) Obesity-related hepatocellular carcinoma: roles of risk factors altered in obesity. Front Biosci 17:2356–2370PubMedCrossRefGoogle Scholar
  31. 31.
    Siddique A, Kowdley KV (2011) Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 15:281–296, vii–xGoogle Scholar
  32. 32.
    Kurmasheva RT, Houghton PJ (2006) IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766:1–22PubMedGoogle Scholar
  33. 33.
    Chen JS, Wang Q, Fu XH et al (2009) Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 39:177–186PubMedCrossRefGoogle Scholar
  34. 34.
    Lawlor MA, Alessi DR (2001) PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114:2903–2910PubMedGoogle Scholar
  35. 35.
    Nam SY, Lee EJ, Kim KR et al (1997) Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 21:355–359PubMedCrossRefGoogle Scholar
  36. 36.
    Aishima S, Basaki Y, Oda Y et al (2006) High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci 97:1182–1190PubMedCrossRefGoogle Scholar
  37. 37.
    Huynh H, Chow PK, Ooi LL et al (2002) A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 13:115–122PubMedGoogle Scholar
  38. 38.
    Alison MR, Nicholson LJ, Lin WR (2011) Chronic inflammation and hepatocellular carcinoma. Recent results in cancer research. Fortschr Krebsforsch 185:135–148Google Scholar
  39. 39.
    Park EJ, Lee JH, Yu GY et al (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197–208PubMedCrossRefGoogle Scholar
  40. 40.
    Ben-Neriah Y, Karin M (2011) Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12:715–723PubMedCrossRefGoogle Scholar
  41. 41.
    Pikarsky E, Porat RM, Stein I et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461–466PubMedCrossRefGoogle Scholar
  42. 42.
    Luedde T, Beraza N, Kotsikoris V et al (2007) Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11:119–132PubMedCrossRefGoogle Scholar
  43. 43.
    He G, Karin M (2011) NF-kappaB and STAT3—key players in liver inflammation and cancer. Cell Res 21:159–168PubMedCrossRefGoogle Scholar
  44. 44.
    He G, Yu GY, Temkin V et al (2010) Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17:286–297PubMedCrossRefGoogle Scholar
  45. 45.
    Ogata H, Kobayashi T, Chinen T et al (2006) Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 131:179–193PubMedCrossRefGoogle Scholar
  46. 46.
    Jequier E (2002) Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 967:379–388PubMedCrossRefGoogle Scholar
  47. 47.
    Sun B, Karin M (2012) Obesity, inflammation, and liver cancer. J Hepatol 56:704–713PubMedCrossRefGoogle Scholar
  48. 48.
    Saxena NK, Sharma D, Ding X et al (2007) Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67:2497–2507PubMedCrossRefGoogle Scholar
  49. 49.
    Chen C, Chang YC, Liu CL et al (2007) Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr Relat Cancer 14:513–529PubMedCrossRefGoogle Scholar
  50. 50.
    Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439–451PubMedCrossRefGoogle Scholar
  51. 51.
    Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMedCrossRefGoogle Scholar
  52. 52.
    Jiang LL, Li L, Hong XF et al (2009) Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur J Gastroenterol Hepatol 21:662–666PubMedCrossRefGoogle Scholar
  53. 53.
    Skrabal CA, Czaja J, Honz K et al (2011) Adiponectin—its potential to predict and prevent coronary artery disease. Thorac Cardiovasc Surg 59:201–206PubMedCrossRefGoogle Scholar
  54. 54.
    Man K, Ng KT, Xu A et al (2010) Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res 16:967–977PubMedCrossRefGoogle Scholar
  55. 55.
    Saxena NK, Fu PP, Nagalingam A et al (2010) Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 139:1762–1773, 1773e1–5Google Scholar
  56. 56.
    Sharma D, Wang J, Fu PP et al (2010) Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 52:1713–1722PubMedCrossRefGoogle Scholar
  57. 57.
    Larsson SC, Wolk A (2007) Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97:1005–1008PubMedGoogle Scholar
  58. 58.
    Oh SW, Yoon YS, Shin SA (2005) Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 23:4742–4754PubMedCrossRefGoogle Scholar
  59. 59.
    Nair S, Mason A, Eason J et al (2002) Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 36:150–155PubMedCrossRefGoogle Scholar
  60. 60.
    N’Kontchou G, Paries J, Htar MT et al (2006) Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 4:1062–1068PubMedCrossRefGoogle Scholar
  61. 61.
    Ohki T, Tateishi R, Shiina S et al (2009) Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 58:839–844PubMedCrossRefGoogle Scholar
  62. 62.
    Petrides AS, Vogt C, Schulze-Berge D et al (1994) Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 19:616–627PubMedCrossRefGoogle Scholar
  63. 63.
    Zein CO, Levy C, Basu A et al (2005) Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 100:48–55PubMedCrossRefGoogle Scholar
  64. 64.
    Angulo P, Keach JC, Batts KP et al (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356–1362PubMedCrossRefGoogle Scholar
  65. 65.
    Adami HO, Chow WH, Nyren O et al (1996) Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88:1472–1477PubMedCrossRefGoogle Scholar
  66. 66.
    Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365PubMedCrossRefGoogle Scholar
  67. 67.
    El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127:S27–S34PubMedCrossRefGoogle Scholar
  68. 68.
    Wang P, Kang D, Cao W et al (2012) Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 28:109–122PubMedCrossRefGoogle Scholar
  69. 69.
    Hardie DG (2007) AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 47:185–210PubMedCrossRefGoogle Scholar
  70. 70.
    Donadon V, Balbi M, Ghersetti M et al (2009) Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 15:2506–2511PubMedCrossRefGoogle Scholar
  71. 71.
    Hassan MM, Curley SA, Li D et al (2010) Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116:1938–1946PubMedCrossRefGoogle Scholar
  72. 72.
    Chen HP, Shieh JJ, Chang CC et al (2013) Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62(4):606–615Google Scholar
  73. 73.
    Blanco-Colio LM, Villa A, Ortego M et al (2002) 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161:17–26PubMedCrossRefGoogle Scholar
  74. 74.
    Rombouts K, Kisanga E, Hellemans K et al (2003) Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 38:564–572PubMedCrossRefGoogle Scholar
  75. 75.
    El-Serag HB, Johnson ML, Hachem C et al (2009) Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136:1601–1608PubMedCrossRefGoogle Scholar
  76. 76.
    Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231PubMedCrossRefGoogle Scholar
  77. 77.
    Browning JD, Szczepaniak LS, Dobbins R et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387–1395PubMedCrossRefGoogle Scholar
  78. 78.
    Fan JG, Zhu J, Li XJ et al (2005) Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 43:508–514PubMedCrossRefGoogle Scholar
  79. 79.
    Brunt EM (2005) Pathology of nonalcoholic steatohepatitis. Hepatol Res 33:68–71PubMedCrossRefGoogle Scholar
  80. 80.
    Torres DM, Harrison SA (2008) Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134:1682–1698PubMedCrossRefGoogle Scholar
  81. 81.
    Williams CD, Stengel J, Asike MI et al (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140:124–131PubMedCrossRefGoogle Scholar
  82. 82.
    Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA (2011) Frequency and outcomes of Liver transplantation for nonalcoholic streatohepatitis in the United States. Gastroenterology 141:1249–1253PubMedCrossRefGoogle Scholar
  83. 83.
    Falck-Ytter Y, Younossi ZM, Marchesini G et al (2001) Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21:17–26PubMedCrossRefGoogle Scholar
  84. 84.
    Caldwell SH, Oelsner DH, Iezzoni JC et al (1999) Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29:664–669PubMedCrossRefGoogle Scholar
  85. 85.
    Poonawala A, Nair SP, Thuluvath PJ (2000) Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case–control study. Hepatology 32:689–692PubMedCrossRefGoogle Scholar
  86. 86.
    Bugianesi E, Leone N, Vanni E et al (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134–140PubMedCrossRefGoogle Scholar
  87. 87.
    Marrero JA, Fontana RJ, Su GL et al (2002) NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36:1349–1354PubMedGoogle Scholar
  88. 88.
    Ratziu V, Bonyhay L, Di Martino V et al (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35:1485–1493PubMedCrossRefGoogle Scholar
  89. 89.
    Sorensen HT, Mellemkjaer L, Jepsen P et al (2003) Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol 36:356–359PubMedCrossRefGoogle Scholar
  90. 90.
    Sanyal AJ, Banas C, Sargeant C et al (2006) Similarities and differences in outcomes of ­cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43:682–689PubMedCrossRefGoogle Scholar
  91. 91.
    Hashimoto E, Yatsuji S, Tobari M et al (2009) Hepatocellular carcinoma in patients with ­nonalcoholic steatohepatitis. J Gastroenterol 44(suppl 19):89–95PubMedCrossRefGoogle Scholar
  92. 92.
    Ascha MS, Hanouneh IA, Lopez R et al (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972–1978PubMedCrossRefGoogle Scholar
  93. 93.
    Hashizume H, Sato K, Takagi H et al (2007) Primary liver cancers with nonalcoholic ­steatohepatitis. Eur J Gastroenterol Hepatol 19:827–834PubMedCrossRefGoogle Scholar
  94. 94.
    Tokushige K, Hashimoto E, Horie Y et al (2011) Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol 46:1230–1237PubMedCrossRefGoogle Scholar
  95. 95.
    Ertle J, Dechene A, Sowa JP et al (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128:2436–2443PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Digestive Disease InstituteCleveland Clinic FoundationClevelandUSA

Personalised recommendations